US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

36.45

+0.20000.55%

Volume:216.28K

Turnover:7.91M

Market Cap:1.42B

PE:-15.30

High:37.43

Open:36.58

Low:35.74

Close:36.25

52wk High:37.43

52wk Low:3.41

Shares:38.87M

Float Shares:28.30M

Volume Ratio:1.20

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3816

EPS(LYR):-2.1918

ROE:-49.17%

ROA:-26.79%

PB:6.46

PE(LYR):-16.63

Loading ...

Overview Company News Filings

Alto Neuroscience Shareholders Shape Governance and Equity Plans

Alto Neuroscience shareholders approved amended 2024 employee stock purchase plan

Wedbush Lifts Price Target on Alto Neuroscience to $24 From $21, Maintains Neutral Rating

MT Newswires Live

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live

Alto Neuroscience publishes corporate presentation on precision psychiatry, biomarker-driven brain drug pipeline

Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate

Benzinga Earnings

Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss

MT Newswires Live

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in treatment-resistant depression

Alto Neuroscience Q1 FY26 net loss widens to $26.2 million; R&D expenses more than doubled to $20.3 million

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS

Alto Neuroscience Inc Q1 EPS $-0.80

THOMSON REUTERS

Alto Neuroscience to present at Bank of America Securities Healthcare Conference

Alto Neuroscience Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

Alto Neuroscience posts Phase 2a ALTO-207 depression trial data showing MADRS improvement

Alto Neuroscience participates in a conference call with H. C. Wainwright

Alto Neuroscience Is Maintained at Buy by Chardan Capital

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience starts Phase 2b ALTO-207 trial in treatment-resistant depression

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ANRO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience Inc","latestPrice":36.45,"timestamp":1787673984543,"preClose":36.25,"halted":0,"volume":216276,"delay":0,"changeRate":0.005517241379310423,"floatShares":28296500,"shares":38870376,"eps":-2.381577,"marketStatus":"Trading","change":0.2,"latestTime":"08-25 12:06:24 EDT","open":36.58,"high":37.43,"low":35.74,"amount":7912357.540488,"amplitude":0.046621,"askPrice":36.54,"askSize":196,"bidPrice":36.4,"bidSize":37,"shortable":3,"etf":0,"ttmEps":-2.381577,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":36.25,"preHourTrading":{"tag":"盘前","latestPrice":37.02,"preClose":36.25,"latestTime":"09:12 EDT","volume":284,"amount":10404.446784,"timestamp":1787663540793,"change":0.77,"changeRate":0.021241,"amplitude":0.026207},"postHourTrading":{"tag":"盘后","latestPrice":36.5,"preClose":36.25,"latestTime":"19:30 EDT","volume":6925,"amount":251486.4535,"timestamp":1787614204847,"change":0.25,"changeRate":0.006897,"amplitude":0.019862},"volumeRatio":1.197758,"impliedVol":0.8266,"impliedVolPercentile":0.4024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":28296500,"roa":"-26.79%","roe":"-49.17%","lyrEps":-2.191806,"volumeRatio":1.197758,"shares":38870376,"dividePrice":0,"high":37.43,"amplitude":0.046621,"preClose":36.25,"low":35.74,"week52Low":3.41,"pbRate":"6.46","week52High":37.43,"institutionHeld":0,"latestPrice":36.45,"committee":-0.682403,"eps":-2.381577,"divideRate":0,"volume":216276,"delay":0,"ttmEps":-2.381577,"open":36.58,"prevYearClose":17.8,"prevWeekClose":34.28,"prevMonthClose":27.07,"prevQuarterClose":26.39,"fiveDayClose":34.13,"twentyDayClose":27.42,"sixtyDayClose":20.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"ANRO","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.65},{"market":"US","date":"2026-05-13","symbol":"ANRO","fiscalQuarterEnding":"2026/03","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2026-03-16","symbol":"ANRO","fiscalQuarterEnding":"2025/12","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-11-12","symbol":"ANRO","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2025-08-13","symbol":"ANRO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.65}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6364,"buy":0.2727,"hold":0.0909,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6364,"analysts":11,"updateTime":1786939200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2026-08-21","current":-15.221007,"percent":0.003231,"low":-16.978804,"twenty":-10.831771,"median":-6.749002,"eighty":-1.49576,"high":-0.793245,"avg":-6.422904,"sd":4.54375,"marketCap":1344042062},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-02","current":-1.079695,"twenty":-10.421079,"median":-6.037568,"eighty":-1.742706,"marketCap":66326716},{"date":"2025-05-09","current":-0.965115,"twenty":-10.40924,"median":-5.975847,"eighty":-1.645994,"marketCap":59287962},{"date":"2025-05-16","current":-1.041186,"twenty":-10.323409,"median":-5.766106,"eighty":-1.583083,"marketCap":65785273},{"date":"2025-05-23","current":-1.255422,"twenty":-10.270134,"median":-5.686944,"eighty":-1.500455,"marketCap":79321337},{"date":"2025-05-30","current":-1.152589,"twenty":-10.199102,"median":-5.617282,"eighty":-1.480737,"marketCap":72824027},{"date":"2025-06-06","current":-1.019763,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"marketCap":64431667},{"date":"2025-06-13","current":-1.049756,"twenty":-10.02004,"median":-5.30697,"eighty":-1.408438,"marketCap":66326716},{"date":"2025-06-20","current":-0.972631,"twenty":-9.987484,"median":-5.077305,"eighty":-1.322054,"marketCap":61453732},{"date":"2025-06-27","current":-0.985485,"twenty":-9.980084,"median":-2.492642,"eighty":-1.263991,"marketCap":62265896},{"date":"2025-07-03","current":-1.006909,"twenty":-9.974165,"median":-2.341082,"eighty":-1.221144,"marketCap":63619503},{"date":"2025-07-11","current":-1.105457,"twenty":-9.589405,"median":-2.272279,"eighty":-1.163435,"marketCap":69846092},{"date":"2025-07-18","current":-1.233999,"twenty":-8.963166,"median":-2.213594,"eighty":-1.13545,"marketCap":77967731},{"date":"2025-07-25","current":-1.319693,"twenty":-8.840728,"median":-2.178383,"eighty":-1.148304,"marketCap":83382157},{"date":"2025-08-01","current":-1.315408,"twenty":-8.760609,"median":-2.161951,"eighty":-1.152589,"marketCap":83111436},{"date":"2025-08-08","current":-1.311123,"twenty":-8.486086,"median":-2.154336,"eighty":-1.163435,"marketCap":82840714},{"date":"2025-08-15","current":-1.302504,"twenty":-8.327763,"median":-2.124393,"eighty":-1.163435,"marketCap":84479082},{"date":"2025-08-22","current":-1.498714,"twenty":-8.182106,"median":-2.122046,"eighty":-1.165443,"marketCap":97205098},{"date":"2025-08-29","current":-1.590557,"twenty":-8.114957,"median":-2.098572,"eighty":-1.169728,"marketCap":103161956},{"date":"2025-09-05","current":-1.465317,"twenty":-8.049126,"median":-2.084227,"eighty":-1.178742,"marketCap":95038967},{"date":"2025-09-12","current":-1.640654,"twenty":-7.979964,"median":-2.075098,"eighty":-1.18912,"marketCap":106411151},{"date":"2025-09-19","current":-1.715798,"twenty":-7.951589,"median":-2.070403,"eighty":-1.198007,"marketCap":111284945},{"date":"2025-09-26","current":-1.586383,"twenty":-7.904286,"median":-2.056319,"eighty":-1.216859,"marketCap":102891190},{"date":"2025-10-03","current":-1.841039,"twenty":-7.881184,"median":-2.039887,"eighty":-1.228,"marketCap":119407933},{"date":"2025-10-10","current":-2.513164,"twenty":-7.867586,"median":-2.056319,"eighty":-1.233142,"marketCap":163001306},{"date":"2025-10-17","current":-2.454718,"twenty":-7.85227,"median":-2.070403,"eighty":-1.244282,"marketCap":159210578},{"date":"2025-10-24","current":-4.667305,"twenty":-7.827138,"median":-2.075098,"eighty":-1.253708,"marketCap":302716712},{"date":"2025-10-31","current":-5.978158,"twenty":-7.812987,"median":-2.084227,"eighty":-1.2897,"marketCap":387737327},{"date":"2025-11-07","current":-4.646431,"twenty":-7.783605,"median":-2.103267,"eighty":-1.301657,"marketCap":301362880},{"date":"2025-11-14","current":-4.738274,"twenty":-7.773873,"median":-2.122046,"eighty":-1.304622,"marketCap":307319739},{"date":"2025-11-21","current":-7.060871,"twenty":-7.758215,"median":-2.12674,"eighty":-1.306199,"marketCap":439588640},{"date":"2025-11-28","current":-6.91117,"twenty":-7.745076,"median":-2.154336,"eighty":-1.306688,"marketCap":430268739},{"date":"2025-12-05","current":-6.67664,"twenty":-7.738804,"median":-2.161951,"eighty":-1.306839,"marketCap":415667562},{"date":"2025-12-12","current":-7.325342,"twenty":-7.736546,"median":-2.178383,"eighty":-1.309247,"marketCap":456053797},{"date":"2025-12-19","current":-9.705579,"twenty":-7.761946,"median":-2.213594,"eighty":-1.311015,"marketCap":604240215},{"date":"2025-12-26","current":-9.920149,"twenty":-7.817318,"median":-2.253904,"eighty":-1.311123,"marketCap":617598739},{"date":"2026-01-02","current":-8.882226,"twenty":-7.875492,"median":-2.303191,"eighty":-1.311123,"marketCap":552980763},{"date":"2026-01-09","current":-7.929133,"twenty":-7.944058,"median":-2.354526,"eighty":-1.311807,"marketCap":493644063},{"date":"2026-01-16","current":-8.493005,"twenty":-8.098499,"median":-2.410079,"eighty":-1.314542,"marketCap":528749021},{"date":"2026-01-23","current":-8.572845,"twenty":-8.233524,"median":-2.467243,"eighty":-1.314542,"marketCap":533719635},{"date":"2026-01-30","current":-7.644703,"twenty":-8.248494,"median":-2.550736,"eighty":-1.315408,"marketCap":475936252},{"date":"2026-02-06","current":-7.040911,"twenty":-8.233524,"median":-2.675047,"eighty":-1.315408,"marketCap":438345986},{"date":"2026-02-13","current":-8.203584,"twenty":-8.278435,"median":-4.258185,"eighty":-1.315408,"marketCap":510730547},{"date":"2026-02-20","current":-9.730529,"twenty":-8.329873,"median":-4.59216,"eighty":-1.315408,"marketCap":605793532},{"date":"2026-02-27","current":-9.625739,"twenty":-8.433125,"median":-4.619295,"eighty":-1.315408,"marketCap":599269602},{"date":"2026-03-06","current":-10.26945,"twenty":-8.504981,"median":-4.688178,"eighty":-1.318836,"marketCap":639345174},{"date":"2026-03-13","current":-11.092803,"twenty":-8.596797,"median":-4.780021,"eighty":-1.319693,"marketCap":690604627},{"date":"2026-03-20","current":-10.997993,"twenty":-8.80207,"median":-5.077305,"eighty":-1.323121,"marketCap":684702023},{"date":"2026-03-27","current":-10.5175,"twenty":-8.978914,"median":-5.159821,"eighty":-1.327405,"marketCap":665105643},{"date":"2026-04-02","current":-11.825873,"twenty":-9.157675,"median":-5.286907,"eighty":-1.342565,"marketCap":747844529},{"date":"2026-04-10","current":-11.315658,"twenty":-9.59795,"median":-5.418318,"eighty":-1.358364,"marketCap":715579558},{"date":"2026-04-17","current":-14.44502,"twenty":-9.715559,"median":-5.499511,"eighty":-1.373177,"marketCap":913474169},{"date":"2026-04-24","current":-14.251015,"twenty":-9.940109,"median":-5.617282,"eighty":-1.380269,"marketCap":901205714},{"date":"2026-05-01","current":-14.2233,"twenty":-9.993374,"median":-5.686437,"eighty":-1.40625,"marketCap":899453077},{"date":"2026-05-08","current":-13.341966,"twenty":-10.092797,"median":-5.762939,"eighty":-1.428579,"marketCap":843719235},{"date":"2026-05-15","current":-11.128225,"twenty":-10.269724,"median":-5.815711,"eighty":-1.431919,"marketCap":826893924},{"date":"2026-05-22","current":-10.161169,"twenty":-10.270134,"median":-5.928061,"eighty":-1.443182,"marketCap":755035825},{"date":"2026-05-29","current":-9.538479,"twenty":-10.26986,"median":-5.978158,"eighty":-1.454447,"marketCap":708766220},{"date":"2026-06-05","current":-9.448849,"twenty":-10.241369,"median":-6.015388,"eighty":-1.46008,"marketCap":702106201},{"date":"2026-06-12","current":-10.121163,"twenty":-10.184016,"median":-6.089518,"eighty":-1.46008,"marketCap":752063134},{"date":"2026-06-18","current":-10.291187,"twenty":-10.191631,"median":-6.176125,"eighty":-1.461019,"marketCap":764696952},{"date":"2026-06-26","current":-11.948923,"twenty":-10.281083,"median":-6.203076,"eighty":-1.464883,"marketCap":887876682},{"date":"2026-07-02","current":-11.778899,"twenty":-10.355847,"median":-6.327685,"eighty":-1.465317,"marketCap":875242863},{"date":"2026-07-10","current":-13.05408,"twenty":-10.419151,"median":-6.392641,"eighty":-1.474164,"marketCap":969996501},{"date":"2026-07-17","current":-14.296657,"twenty":-10.441725,"median":-6.422411,"eighty":-1.474164,"marketCap":1062327376},{"date":"2026-07-24","current":-14.045563,"twenty":-10.492111,"median":-6.506979,"eighty":-1.478859,"marketCap":1043669595},{"date":"2026-07-31","current":-14.976703,"twenty":-10.518342,"median":-6.61177,"eighty":-1.482615,"marketCap":1112858864},{"date":"2026-08-07","current":-14.893005,"twenty":-10.61405,"median":-6.65169,"eighty":-1.485663,"marketCap":1106639604},{"date":"2026-08-14","current":-15.04689,"twenty":-10.749604,"median":-6.68163,"eighty":-1.487837,"marketCap":1267519959},{"date":"2026-08-21","current":-15.955294,"twenty":-10.831771,"median":-6.749002,"eighty":-1.49576,"marketCap":1344042062}],"updateTime":1787642040264},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635751636","title":"Alto Neuroscience Shareholders Shape Governance and Equity Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751636?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:38","pubTimestamp":1778708298,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has shared an announcement. On May 12, 2026, Alto Neuroscience, Inc. held its Annual Meeting, at which stockhol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-shareholders-shape-governance-and-equity-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-shareholders-shape-governance-and-equity-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4588","BK4215","EQR","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635530687","title":"Alto Neuroscience shareholders approved amended 2024 employee stock purchase plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2635530687","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635530687?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:27","pubTimestamp":1778704028,"startTime":"0","endTime":"0","summary":"Alto Neuroscience held its annual shareholder meeting on May 12, 2026.Amendment and restatement of 2024 Equity Incentive Plan failed to win shareholder support, leaving unchanged proposal to treat outstanding pre-funded warrants like common shares for automatic share reserve increases.Amendment and restatement of 2024 Employee Stock Purchase Plan was adopted, authorizing same pre-funded warrant treatment for automatic share reserve increases under plan’s evergreen feature.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLp072h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635673930","title":"Wedbush Lifts Price Target on Alto Neuroscience to $24 From $21, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635673930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635673930?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:46","pubTimestamp":1778687192,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) has an average rating of buy and mean price target of $35.52, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780327","title":"Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780327?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:16","pubTimestamp":1778678166,"startTime":"0","endTime":"0","summary":"Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF  down 0.2% and the iShares Biotechnology ETF  declining by 0.5%.National Vision Holdings  stock was down more than 11% after the company reported fiscal Q1 revenue that missed analysts' estimates.Alto Neuroscience  shares were down more than 3% after the company posted a wider Q1 net loss.Personalis  said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services has expanded coverage for the firm's NeXT Personal minimal residual disease test. Personalis stock was up more than 14% premarket.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSNL","BK4137","HCSG","BK7007","BK4585","LU0128526141.USD","LABU","BK4200","XLV","BK4588","BK4121","LU0053671581.USD","LU1559883803.SGD","ANRO","EYE.AU","BK4581","IBB","XBI","EYE","LU0029874061.USD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635871017","title":"Alto Neuroscience publishes corporate presentation on precision psychiatry, biomarker-driven brain drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635871017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635871017?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:01","pubTimestamp":1778677304,"startTime":"0","endTime":"0","summary":"Alto Neuroscience outlined a biomarker-driven precision psychiatry strategy, targeting patient selection to improve response rates and reduce late-stage development risk.Lead program ALTO-207 for treatment-resistant depression remains in Phase 2b, with topline data expected in 2H 2027; Phase 3 initiation planned by early 2027.ALTO-300 for major depressive disorder is in Phase 2b, with topline data expected in 1H 2027; ALTO-208 for bipolar depression is in Phase 2b, with topline data expected mid-2027.ALTO-207 combines pramipexole with ondansetron, aiming to improve tolerability and enable faster titration; Phase 2a results cited an average 4.1 mg/day pramipexole dose reached in 8 days with a Week 8 MADRS placebo-adjusted reduction of 8.2 points.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8R47Vz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789136","title":"Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789136","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789136?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:25","pubTimestamp":1778671522,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52518212/alto-neuroscience-q1-eps-0-80-misses-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748786","title":"Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748786","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748786?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670764,"startTime":"0","endTime":"0","summary":"Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786434","title":"Alto Neuroscience initiates Phase 2b trial of ALTO-207 in treatment-resistant depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786434","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786434?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:08","pubTimestamp":1778670539,"startTime":"0","endTime":"0","summary":"Alto Neuroscience initiated Phase 2b randomized, double-blind, placebo-controlled trial of ALTO-207 as adjunctive treatment for adults with treatment-resistant depression in first quarter 2026, positioning program for a potential registrational pathway.Trial will test whether ALTO-207 can replicate antidepressant benefits seen previously with pramipexole, with topline results expected in 2H 2027.Separate Phase 2 proof-of-concept results for ALTO-101 in cognitive impairment associated with schizophrenia were already presented, missing primary biomarker endpoint while showing signals consistent with potential benefits on broader cognition and attention measures.Cash, cash equivalents, and restricted cash totaled USD 264.2 million at March 31, 2026, following USD 120 million PIPE financing, with runway expected through 2029 including planned ALTO-207 Phase 3 start in early 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3l1hrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786178","title":"Alto Neuroscience Q1 FY26 net loss widens to $26.2 million; R&D expenses more than doubled to $20.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786178","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786178?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:06","pubTimestamp":1778670397,"startTime":"0","endTime":"0","summary":"Alto Neuroscience posted a net loss of USD 26.2 million for quarter ended March 31, 2026, widening from a net loss of USD 15.2 million a year earlier.R&D expenses more than doubled to USD 20.3 million, while G&A expenses rose to USD 6.8 million.Cash, cash equivalents, restricted cash climbed to USD 264.2 million from USD 177.0 million as of Dec. 31, 2025, reflecting net proceeds of about USD 115 million from a March PIPE.Phase 2b trial of ALTO-207 in treatment-resistant depression was initiated in April; Phase 3 initiation remains targeted for early 2027, with Phase 2b topline data guided for 2H 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief vi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1MSS02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866807","title":"Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635866807?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:03","pubTimestamp":1778670180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA5SVGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786166","title":"Alto Neuroscience Inc Q1 EPS $-0.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786166?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:03","pubTimestamp":1778670180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA5SVGM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634322092","title":"Alto Neuroscience to present at Bank of America Securities Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2634322092","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634322092?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529952,"startTime":"0","endTime":"0","summary":"Alto Neuroscience management to present at Bank of America Securities Healthcare Conference in Las Vegas on May 13, 2026 at 5:15 pm PDT.Jefferies Global Healthcare Conference appearance set for June 3, 2026 at 9:20 am EDT in New York.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL5zWHxs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634123919","title":"Alto Neuroscience Price Target Maintained With a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634123919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634123919?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:48","pubTimestamp":1778521680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 13:48 ET (17:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634723532","title":"Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634723532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634723532?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:50","pubTimestamp":1778514615,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ginkgo-bioworks-holdings-dna-xencor-xncr-and-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ginkgo-bioworks-holdings-dna-xencor-xncr-and-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4137","BK4139","XNCR","LU0029874061.USD","BK4581","BK4109","LABU","DNA","BK4121","ANRO","BK4007","BK4585","HCSG","LU0128526141.USD","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632229953","title":"Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2632229953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632229953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:31","pubTimestamp":1777897864,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 in patie...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4109","BK4138","ANRO","BK4139","BK4007","ALTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632587529","title":"Alto Neuroscience posts Phase 2a ALTO-207 depression trial data showing MADRS improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2632587529","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632587529?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:07","pubTimestamp":1777896471,"startTime":"0","endTime":"0","summary":"Alto Neuroscience presented Phase 2a trial results for depression drug candidate ALTO-207 at 2026 Society of Biological Psychiatry annual meeting.Study showed meaningful improvement in depressive symptoms versus placebo, supporting further development of fixed-dose pramipexole-ondansetron combination.Trial results indicated patients were able to reach higher pramipexole doses more quickly, addressing tolerability issues that have limited use of pramipexole in routine care.No maintenance-phase discontinuations tied to adverse events were reported in ALTO-207 arm, with nausea remaining an observed side effect.Company advanced ALTO-207 into Phase 2b trial in treatment-resistant depression, with updated titration schedule aimed at improving tolerability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL61B9Vw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631654404","title":"Alto Neuroscience participates in a conference call with H. C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2631654404","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631654404?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:18","pubTimestamp":1777483112,"startTime":"0","endTime":"0","summary":"Healthcare Analyst Trucchio holds a conference call with CEO Etkin to discuss Alto’s precision psychiatry pipeline on May 5 at 12 pm hosted by H.C....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-participates-in-a-conference-call-with-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-participates-in-a-conference-call-with-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4581","XLV","BK4585","ANRO","BK4007","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629020583","title":"Alto Neuroscience Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2629020583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629020583?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:12","pubTimestamp":1776888720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 16:12 ET (20:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629055385","title":"Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629055385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629055385?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:40","pubTimestamp":1776786008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcus Biosciences (RCUS) and Alto Neuroscience, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arcus-biosciences-rcus-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arcus-biosciences-rcus-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4588","XLV","LABU","ANRO","BK4139","LU0029874061.USD","LU0128526141.USD","BK4007","BK4581","HCSG","BK4585","XBI","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629702036","title":"Alto Neuroscience starts Phase 2b ALTO-207 trial in treatment-resistant depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2629702036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629702036?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:08","pubTimestamp":1776773327,"startTime":"0","endTime":"0","summary":"Alto Neuroscience initiated a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression.Study aims to replicate previously published results for pramipexole augmentation while improving tolerability through ALTO-207’s fixed-dose combination with ondansetron.Trial will enroll about 178 adults, with an eight-week treatment period at sites in United States and United Kingdom.Topline results will be presented in second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3mVrnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":110,"code":"91000000","status":"200"}]}}